Purchase Order 75F40123P00293
Award Date 8/15/23
Potential Completion Date 8/14/24
Potential Value $23K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award is for the purchase of NanoString reagents for bioassay gene expression development, with a ceiling value of $65,888.00. The contract was awarded to Nanostring Technologies, Inc., a publicly traded provider of advanced genomic analysis platforms and life science tools. The contract is a firm fixed-price purchase order with the Food and Drug Administration, a civilian federal agency. The contract does not have a set-aside designation. Nanostring Technologies has...
- The Food and Drug Administration awarded a $206,125 firm fixed-price purchase order to NanoString Technologies, Inc., a publicly traded provider of advanced genomic analysis platforms and life science tools, for four option years of preventive maintenance services on an nCounter Sprint Profiler Instrument. The contract, which carries a Total Small Business set-aside designation, was awarded on June 21, 2022, with an ultimate completion date of July 31, 2027. The place of performance is...
- Nanostring Technologies, Inc. has been awarded a firm fixed price purchase order valued at $22,941 by the National Institutes of Health National Institute of Allergy and Infectious Diseases. The award has no set-aside designation and work is to be completed by December 31, 2023. As a manufacturer of life science tools for translational research and molecular diagnostics, Nanostring will likely provide specialized equipment, consumables, or services to support genomic and molecular analysis...
- Nanostring Technologies, Inc. was awarded a $24,659 firm fixed price call order under a blanket purchase agreement (BPA) with the National Institute of Environmental Health Sciences (NIEHS), a component of the National Institutes of Health. The award, issued on May 28, 2024, with a completion date of September 30, 2024, was made without a set-aside designation. The work will be performed at Nanostring's facility in Seattle, Washington. This call order represents a continuation of Nanostring's...
- Nanostring Technologies, Inc. was awarded a firm fixed price contract valued at $24,818.90 by the National Institute of Environmental Health Sciences on August 10, 2020, with an ultimate completion date of September 8, 2020. This award was issued as a call under an existing blanket purchase agreement (BPA) and did not utilize any set-aside designation. The contract is for products and services related to Nanostring's advanced genomic analysis platforms, which the vendor supplies to support the...
- This $93,359 firm fixed-price purchase order was awarded to Nanostring Technologies, Inc., a publicly traded provider of advanced genomic analysis platforms and life science tools, by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract is for the delivery of Nanostring's proprietary nCounter and GeoMx analysis systems, reagents, and consumables to support genomic, molecular, and cellular...
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a firm-fixed-price purchase order to Nanostring Technologies, Inc., a publicly held provider of life science tools, for HU V3 MIRNA REAGENTS. The contract has a potential value of $24,339.90 and a completion date of September 5, 2023. Nanostring Technologies has an extensive history of providing specialized laboratory equipment, consumables, and testing services to support genomic,...
- Nanostring Technologies, Inc. received a $24,818.90 firm fixed price call against a blanket purchase agreement from the National Institute of Environmental Health Sciences on August 26, 2020, with an ultimate completion date of August 31, 2020. The contract, which carries no set-aside designation, was performed in Seattle, Washington. As a call against an existing BPA, this award represents a specific delivery order for Nanostring's genomic analysis products or services to support the agency's...
- The National Institute of Environmental Health Sciences awarded a $11,007 firm fixed price contract to Nanostring Technologies, Inc. on April 18, 2017, with an ultimate completion date of August 31, 2017. This award was issued as a call against an existing blanket purchase agreement and did not utilize a set-aside designation. The work was performed in Seattle, Washington, and involved the delivery of specialized laboratory equipment, reagents, assays, or related consumables from Nanostring's...
- Nanostring Technologies, Inc. has been awarded a firm fixed price purchase order valued at ten thousand two hundred twenty four dollars by the National Institutes of Health's National Institute of Allergy and Infectious Diseases. Under the contract, Nanostring will provide its XT HS HostResponse assay kits and related supplies to support the NIH's infectious disease research efforts. As the prime contractor, Nanostring will deliver four assay kits priced at three thousand three hundred eleven...
The Department of Health and Human Services Food and Drug Administration awarded a $22,766 purchase order to Nanostring Technologies, Inc. for the procurement of Nanostring cassettes and reagents. The firm fixed price contract has a period of performance from August 15, 2023 through August 14, 2024 and will be performed in Silver Spring, Maryland. The award is set aside for total small businesses. As the prime contractor, Nanostring will provide its proprietary gene expression analysis products to support the FDA's regulatory and research efforts in advancing precision medicine and developing new diagnostics and treatments.
Generated 12/23/23, 3:55 PM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.8k | 8/15/23 |